[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
July 14, 1934

Government Services

JAMA. 1934;103(2):119. doi:10.1001/jama.1934.02750280039018

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


Trade Commission Charges Misrepresentation in Bayer Aspirin Advertising  The Federal Trade Commission has filed a complaint charging misrepresentation in connection with the sale of acetylsalicylic acid tablets against the Bayer Company, Inc., New York. The commission alleges that the company's advertising tends to mislead buyers into believing that "Bayer aspirin" is the only genuine acetylsalicylic acid, intimating that the product sold by its competitors is not "aspirin," is not as beneficial as the Bayer product, and is counterfeit or spurious. According to the complaint, Bayer advertising has proclaimed that its tablets will quickly relieve any and every pain and that any user may safely take as many tablets as necessary to relieve pain or to cure disease or sleeplessness. Relying on medical opinion, the commission stated that there are persons who cannot take such tablets safely even in small or moderate doses, others who cannot take more than the usual

First Page Preview View Large
First page PDF preview
First page PDF preview